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Abstract 1 
 2 
Although several studies indicate that meningoencephalitis of unknown 3 
aetiology (MUA) might affect every dog breed at every age, little is known about 4 
clinical presentation, diagnostic findings and long-term survival in large breed dogs. 5 
The aim of this study was therefore to compare the clinical presentation, diagnostic 6 
findings and long-term survival between large and small/medium breed dogs diagnosed 7 
with MUA. One hundred and eleven dogs met the inclusion criteria. Twenty-eight 8 
(25%) dogs were considered large breed dogs, compared to 83 (75%) small/medium 9 
breed dogs. Large breed dogs presented significantly more often with a decreased 10 
mentation. Age, gender, duration of clinical signs prior to diagnosis, presence of 11 
seizures or cluster seizures, variables on complete blood count and cerebrospinal fluid 12 
analysis, and all variables on MRI were not significantly different between 13 
small/medium and large breed dogs. Median survival time was 281 and 106 days for 14 
the large and small/medium breed dogs respectively, with no significant difference in 15 
survival curves for both groups. Although considered not typically affected by MUA, 16 
25% of dogs included in this study were considered large breed dogs. Therefore, MUA 17 
should be included in the differential diagnosis for large breed dogs presenting with 18 
intracranial neurological signs. If diagnosed with MUA, large breed dogs also carried 19 
a guarded prognosis.   20 
 21 
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  1 
Introduction 1 
Meningoencephalitis of unknown aetiology (MUA) is a group of idiopathic 2 
non-infectious central nervous system (CNS) diseases, with a likely multifactorial 3 
pathogenesis (Talarico and Schatzberg 2010). The term MUA has been introduced to 4 
encompass all clinically diagnosed cases of non-infectious inflammatory diseases of 5 
the CNS with lacking of histopathological confirmation. More specific, this group 6 
includes encephalopathies such as granulomatous meningoencephalitis (GME), 7 
necrotising meningoencephalitis (NME) and necrotising leucoencephalitis (NLE) 8 
(Zarfoss and others 2006; Talarico and Schatzberg 2010). Middle-aged female toy and 9 
terrier breeds are considered predisposed to develop GME (Munana and Luttgen 1998; 10 
Adamo and others 2007; Talarico and Schatzberg 2010). Necrotising encephalitis 11 
(including NME and NLE) predominantly affects toy and small breed dogs including 12 
Yorkshire Terrier, Maltese Terrier, French Bulldog, Shih Tzu, Lhasa Apso, Chihuahua, 13 
Pug, Pekingese, Papillon, Coton de Tulear and Brussels Griffon (Talarico and 14 
Schatzberg 2010; Cooper and others 2014). Although it is stated that dogs of any breed 15 
and age can be affected by MUA (Coates and Jeffery 2014), literature regarding 16 
differences in clinical presentation, diagnostic findings and long-term survival between 17 
small/medium and large breed dogs is currently unavailable. It is unknown whether the 18 
non-infectious inflammatory encephalopathies diagnosed in large breed dogs are just a 19 
variation on a common etiologic theme or represent a truly different aetiology 20 
compared to the various almost breed-specific encephalitides regularly diagnosed in 21 
small/medium breed dogs. The aims of this study where therefore to describe the 22 
clinical presentation, diagnostic findings and long-term survival in large breed dogs 23 
diagnosed with MUA compared to small/medium breed dogs. We hypothesized that no 24 
differences would be detected in clinical presentation, diagnostic findings and long-1 
term survival between small/medium and large breed dogs diagnosed with MUA.  2 
 3 
Materials and methods 4 
Case selection  5 
The electronic medical database of the Small Animal Referral Hospital, Royal 6 
Veterinary College, University of London, was searched between January 2006 and 7 
April 2015 for dogs diagnosed with “MUO”, “MUA”, “GME”, “NME”, “NLE”, 8 
“inflammatory CNS disease”, “non-infectious meningoencephalitis” and the fully 9 
written versions of the above-mentioned abbreviations. Dogs were included based on 10 
the criteria used by Granger and others (2010), if they had (1) complete medical records 11 
available, (2) a complete neurological examination performed leading to a focal or 12 
multifocal intracranial neuroanatomical localisation, (3) inflammatory CSF analysis, 13 
(4) MR imaging of the brain demonstrating single, multiple or diffuse intra-axial 14 
hyperintense lesions on T2W images, and (5) outcome data available through revision 15 
of medical records or contacting the referring veterinarian by email or telephone. Dogs 16 
were excluded if (1) the clinical records or imaging studies were incomplete or not 17 
available for review, (2) dogs were diagnosed with meningomyelitis without clinical 18 
signs of intracranial involvement, (3) no pleocytosis was found on CSF analysis with 19 
the exception of dogs with signs of raised intracranial pressure (ICP) on imaging 20 
studies, in which case CSF collection was not performed, and if (4) outcome data were 21 
unavailable. Dogs with histopathological confirmation of the disease only needed to 22 
fulfil inclusion criteria (1) and (5).  23 
Dogs weighing > 15kg were considered large breed dogs, dogs <15kg were 24 
considered small/medium breed dogs. For dog breeds were the body weight varied 25 
around 15kg, mean body weight for male and female dogs as reported on the Kennel 1 
Club website (http://www.thekennelclub.org.uk/services/public/breed/standard-2 
find.aspx) were used to consider them large or medium/small breed dogs. Information 3 
retrieved from the medical records included breed, age at diagnosis, gender, body 4 
weight, results of general physical and neurological examination and neuroanatomical 5 
localisation, duration of clinical signs prior to diagnosis, results of complete blood 6 
count (CBC) and biochemistry profile, results of CSF analysis, and lactate 7 
concentration on venous blood gas analysis. Duration of clinical signs prior to diagnosis 8 
was classified as peracute (<2 days), acute (2–7 days) or chronic (>7 days). For dogs 9 
that had CSF analysis performed, site of collection (cisternal or lumbar), total nucleated 10 
cell count (TNCC), total protein concentration (TP) and nucleated cell differential count 11 
were recorded. Total nucleated cell count was considered normal if the TNCC < 5 12 
cells/mm3. Protein concentration was considered normal for a cisternal collection if < 13 
0,25 g/l and for a lumbar collection if < 0,4 g/l. Possible neuroanatomical localisations 14 
included forebrain, brainstem or cerebellum. Dogs with vestibular signs attributable to 15 
an intracranial lesion were diagnosed with central vestibular signs. If more than 2 of 16 
the above mentioned regions appeared to be affected on the neurological examination, 17 
dogs were given a multifocal neuroanatomical localisation, where dogs with only one 18 
region affected were given a focal neuroanatomical localisation. Magnetic resonance 19 
imaging was performed under general anaesthesia with a permanent 1.5T magnet 20 
(Intera, Philips Medical Systems, Eindhoven, the Netherlands) and all images were 21 
reviewed by a board certified neurologist (SDD) using Osirix DICOM viewer (Osirix 22 
Foundation, V.5.5.2 Geneva, Switzerland). The reviewer was blinded for signalment, 23 
results of the neurological examination and necropsy findings if available. Sequences 24 
could vary, but studies included a minimum of T2-weighted (T2W) (repetition time 25 
(ms) (TR)/echo time (ms) (TE), 3000/120), T1-weighted (T1W) (TR/TE, 400/8) and 1 
fluid attenuating inversion recovery (FLAIR) images of the entire brain in a sagittal, 2 
transverse and dorsal plane. The T1W images were acquired before and after IV 3 
administration of paramagnetic contrast medium (0,1 mg/kg, gadoterate meglumine, 4 
Dotarem, Guerbet, Milton Keynes, UK). Variables recorded were lesion localisation 5 
and distribution, presence of parenchymal or meningeal contrast enhancement and 6 
presence of mass effect (brain herniation, midline shift, flattening of gyri/sulci).  7 
 8 
Statistical analysis 9 
Data analysis was performed with the aid of a standard statistical software 10 
package (Prism, Graphpad Software Inc, La Jolla, California, USA). A Mann-Whitney 11 
U test was used to compare age, duration of clinical signs prior to diagnosis, venous 12 
blood lactate levels, white blood cell (total, neutrophil and lymphocyte) count on CBC, 13 
TNCC and TP concentration in CSF between small/medium and large breed dogs. A 14 
fisher’s exact test was used to compare differences in gender, presence of seizures and 15 
cluster seizures, neuroanatomical localization (mentation, forebrain, brainstem, central 16 
vestibular) and imaging findings (lesion localization, meningeal or parenchymal 17 
contrast enhancement, mass effect, brain herniation, flattening gyri/sulci, rostral or 18 
caudal transtentorial herniation, foramen magnum herniation) between small/medium 19 
and large breed dogs. Numeric variables were expressed as median and IQR. A false 20 
discovery rate (FDR) as used by Benjamini and others (2001) was applied to control 21 
for the increased risk of falsely significant results in the multiple comparisons. Values 22 
of P<0.05 were considered significant. Survival analysis was performed using both a 23 
Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxin test, resulting in median survival 24 
time (MST) calculation and Kaplan-Meier survival curves comparing survival 25 
percentage in small/medium and large breed dogs. Survival was defined as time from 1 
diagnosis to death or euthanasia, including whether this happened because of disease 2 
progression or due to unrelated causes, or time from diagnosis to data collection for 3 
dogs that were alive at time of data capture. Dogs that died because of unrelated causes 4 
and dogs that were still alive at time of data capture were censored for calculations.  5 
 6 
 7 
Results 8 
Signalment 9 
Database research revealed 549 results. Dogs were excluded if they did not 10 
match the inclusion criteria, or if they strictly met the inclusion criteria, but the 11 
combination of clinical presentation and imaging findings was more suggestive for 12 
another intracranial disorder (neoplasia, vascular lesion) was considered more 13 
likely. Finally, 111 dogs were included in this study. These included 28 (25%) large 14 
breed and 83 (75%) small/medium breed dogs. Large breed dogs represented were 15 
English Springer Spaniel (n=6), cross breed (n=5), Labrador Retriever (n=4), Golden 16 
Retriever (n=2), Akita (n=2), and one each of the following breeds: Border Collie, 17 
Boxer, Bernese Mountain dog, Curly-Coated Retriever, German Wirehaired pointer, 18 
Great Dane, Shar-Pei, Siberian Husky, Welsh Springer Spaniel. Compared to the 19 
general hospital population admitted between January 2006 and April 2015, English 20 
Springer Spaniels were not significantly overrepresented (P=0.196). Small breeds 21 
included West Highland White terrier (n=22), Chihuahua (n=8), Maltese terrier (n=8), 22 
Pug (n=8), French Bulldog (n=7), Cavalier King Charles Spaniel (n=6), crossbreed 23 
(n=6), Yorkshire terrier (n=5), Border terrier (n=2), Boston terrier (n=2), Pomeranian 24 
(n=2), Poodle (n=2) and one each of the following breeds: Bichon Frise, Welsh Corgi 1 
Cardigan, Lhasa Apso, Papillon and Sheltie.  2 
 3 
Clinical presentation and diagnostic findings  4 
Large breed dogs had a significant shorter duration of clinical signs prior to 5 
diagnosis (P=0.012), more often presented with decreased mentation (<0.0001) and less 6 
often with cranial nerve deficits (P=0.027), and were more often diagnosed with a 7 
brainstem lesion on MRI (P=0.039) compared to small/medium breed dogs. However, 8 
when a FDR of 10% was applied, only decreased mentation was found to be 9 
significantly different between both groups (table 1). Gender, age at presentation, 10 
neuroanatomical localisation, presence of seizures and cluster seizures, lactate 11 
concentration on venous blood gas analysis, TNCC and TP concentration on CSF 12 
analysis and the remaining MRI findings (meningeal or parenchymal contrast 13 
enhancement, mass effect, brain herniation, flattening gyri/sulci, rostral or caudal 14 
transtentorial herniation, foramen magnum herniation) were not different between 15 
small/medium and large breed dogs. All statistical results can be consulted in table 1, 16 
a clinical summery regarding the large breed dogs can be consulted in table 2.  17 
Serological testing and/or polymerase chain reaction (PCR) for Canine 18 
Distemper virus, Toxoplasma gondii and Neospora caninum was performed in 19 19 
(68%) large breed dogs and in 59 (71%) small/medium breed dogs. Of the 9 large breed 20 
dogs that did not undergo infectious disease testing, 1 dog had complete necropsy 21 
performed and 4 dogs were still alive at time of data capture with survival times ranging 22 
from 184 – 2039 days. These 4 dogs were all treated with an immunosuppressive 23 
treatment protocol. The 4 remaining large breed dogs died within 20 days after 24 
diagnosis and breeds included English Springer Spaniel, crossbreed, Siberian Husky 1 
and Akita.  2 
Post-mortem examination was performed in 14 dogs, 8 small/medium breed and 3 
6 large breed dogs. Results included GME (5 small/medium breed, 4 large breed), NME 4 
(3 small breed, 1 large breed) and NLE (1 large breed dog). 5 
 6 
Outcome 7 
All 111 dogs were initiated on immunosuppressive doses of 8 
glucocorticosteroids at time of diagnosis, combined with cytosine arabinoside in 66 9 
(80%) small/medium breed dogs and 18 (64%) large breed dogs. Most dogs on cytosine 10 
arabinoside therapy had regular (3-4 weekly) re-examinations at a dedicated cytosine 11 
arabinoside clinic. Overall, dogs that were alive at time of data capture, were dogs that 12 
received sole prednisolone therapy or combined prednisolone and cytosine arabinoside 13 
treatment.  14 
At time of data capture, 11 (39%) large breed dogs and 27 (33%) small/medium 15 
breed dogs were alive. Conversely, 17 (61%) large breed and 56 (67%) small/medium 16 
breed dogs had died. Of the deceased dogs, 15 (88%) large breed dogs and 47 (84%) 17 
small/medium breed dogs died or were euthanized because of disease progression, 18 
compared to 2 (12%) large breed dogs and 9 (16%) small/medium breed dogs that died 19 
or were euthanized for unrelated causes. Overall, 54% of the large breed dogs and 57% 20 
of the small/medium breed dogs died or were euthanized because of disease 21 
progression. The MST was 281 days and 106 days for the small/medium and large 22 
breed dogs respectively. There was no significant difference in survival curves between 23 
small/medium and large breed dogs (P=0.664) (Figure 1). 24 
 25 
Discussion  1 
This study evaluated the differences in clinical presentation, diagnostic findings 2 
and long-term survival between small/medium and large breed dogs diagnosed with 3 
MUA. Large breed dogs were found to present significantly more often with a 4 
decreased mentation. No significant difference was seen in survival curves between 5 
small/medium and large breed dogs. To the best of our knowledge, this is the first study 6 
describing clinical, diagnostic and outcome data in large breed dogs with MUA. 7 
Meningoencephalitis of unknown aetiology is generally considered a syndrome 8 
affecting small, toy and terrier breed dogs aged between approximately 3 and 7 years 9 
(Munana and Luttgen 1998; Adamo and others 2007; Talarico and Schatzberg 2009; 10 
Coates and Jeffery 2014). However, a total of 47 large breed dogs are present in the 11 
literature from 1998 to 2015. The distribution of the breeds in our study appears to be 12 
similar. Although the English Springer Spaniel was the most common large dog breed 13 
in our study, it was not significantly overrepresented compared to the general hospital 14 
population. The higher number of this breed in our study therefore likely reflects its 15 
popularity in the United Kingdom. MUA occurred, as expected, more often in 16 
small/medium breed dogs, but still a quarter of dogs in the presented study were large 17 
breed dogs. Ignoring this population of dogs would underestimate the prevalence of 18 
MUA in the overall canine population. Therefore, MUA should be considered as a 19 
differential diagnosis in dogs other than small or toy breeds that have signs suggestive 20 
of inflammatory brain disease.  21 
 22 
Large breed dogs were more likely to present with a decreased mentation 23 
compared to their small/medium breed counterparts. Abnormal mentation in dogs can 24 
be caused by lesions in the forebrain (telencephalon and diencephalon) and/or 25 
brainstem (mesencephalon, metencephalon, myelencephalon) (Garosi 2013). A lesion 1 
in the brainstem is considered a typical MRI finding in cases of GME and NLE, but is 2 
considered an uncommon finding in dogs with NME (Coates and Jeffery 2014). 3 
However, histopathological lesions have been identified in the brainstem of Chihuahua 4 
and Pug dogs with NME (Higgins and others 2008; Park and others 2012). In the 5 
presented study, both small/medium and large breed dogs were histopathologically 6 
diagnosed with GME and NME, and 1 large breed dogs was diagnosed with NLE, 7 
which has not yet been previously described. In literature, NLE is mainly affecting 8 
Yorkshire terriers, Maltese Terriers and a French Bulldog (Schatzberg 2005; 9 
Higginbotham and others 2007; Timmann and others 2007; Spitzbarth and others 10 
2010), which are all considered small/medium breed dogs in this study. Necrotising 11 
meningoencephalitis has only been once previously described in large breed dog; a 12 
26kg Staffordshire Bull Terrier mix (Estey and others 2014).  13 
 14 
A limitation of the current study is the lack of histopathological confirmation in 15 
the majority of cases, which makes inclusion of other diseases than MUA possible 16 
(mainly cerebrovascular or neoplastic disease). Based on intracranial MRI, seven 17 
imaging abnormalities have been associated with neoplastic brain disease in one study 18 
(Cherubini and others 2005). These included the presence of a single lesion, regular 19 
lesion shape, presence of mass effect, dural contact, dural tail sign, lesions affecting 20 
adjacent bone and contrast enhancement (Cherubini and others 2005). Another study 21 
demonstrated MRI to be 94.4% sensitive and 95.5% specific for detection of a brain 22 
lesion and for classifying neoplastic and inflammatory disease correctly, but was only 23 
38.9% sensitive for classifying cerebrovascular disease (Wolff and others 2012). For 24 
the presented study, 6 large breed dogs had a focal lesion on MRI of the brain, where 25 
inflammatory lesions are more typically associated with multifocal or diffuse lesions 1 
on intracranial imaging (Cherubini and others 2006). Two of those lesions were 2 
histopathologically confirmed as GME or NME. Of the 4 remaining dogs, one dog 3 
(Siberian husky) had a focal lesion in the frontal lobe that showed presence of mass 4 
effect, parenchymal contrast enhancement and dural contact. Although abnormalities 5 
on CSF-analysis do not exclude neoplastic or vascular disease (REF), this dog had an 6 
increased TNCC (35 WBC/mm3) and TP concentration (0.35 g/l) on cisternal CSF 7 
analysis. The dog was only 30 months old, and died acutely at home 18 days after 8 
diagnosis after initial improvement on immunosuppressive therapy. The second, third 9 
and fourth dog (2 cross breeds and an English Springer Spaniel) were 26 – 85 months 10 
old at time of diagnosis and had a focal lesion in the piriform lobe (crossbreed) or 11 
brainstem (cross breed an English Springer Spaniel). All three dogs had increased 12 
TNCC and TP concentrations on cisternal CSF analysis, and all were alive 1095 – 1580 13 
days after diagnosis. All dogs had an acute onset of neurological signs, which might 14 
still be compatible with cerebrovascular disease, which might be supported by the long 15 
survival without treatment of those dogs. However, in cerebrovascular disease, contrast 16 
enhancement should only be visible after 7-10 days in dogs with ischaemic infarcts, 17 
and after 6 days to 6 weeks in dogs with haemorrhagic infarcts (Garosi 2012). All dogs 18 
with a focal lesion had intracranial imaging within 5 days after onset of neurological 19 
signs, and all lesions showed parenchymal contrast enhancement, which was 20 
considered less typical for cerebrovascular disease. Neoplastic disease can however not 21 
be excluded in those cases, although all 4 dogs were still young at time of diagnosis (2-22 
5y of age) where brain tumors are typically affecting middle-aged to older (over 5 23 
years) dogs and cats, with the majority being greater than 9 years of age (Dickinson 24 
2014; Snyder and others 2006). 25 
Infectious disease testing was lacking in approximately 30% of both 1 
small/medium and large breed dogs. The 9 large breed dogs that were not tested had 2 
focal (n=2), multifocal (n=5) or diffuse forebrain (n=2) lesions on MR imaging. 3 
Necrotising cerebellitis and cerebellar atrophy (Garosi and others 2010) as well as 4 
multifocal brain involvement (Parzefall and others 2014) have been described in 5 
association with Neospora caninum infection in dogs. In the study of Parzefall and 6 
others (2014), mild cerebellar atrophy was additionally seen in 3 of 4 dogs. In the 7 
presented study, 11 large breed dogs died within 20 days after diagnosis and after 8 
immunosuppressive treatment. Necropsy confirming GME, NLE or NME was 9 
performed in 6/11 dogs. Of the 5 remaining dogs, all but 1 (Siberian Husky) had 10 
multifocal or diffuse forebrain lesions without cerebellar involvement, and showed no 11 
signs of perilesional edema on FLAIR images as described by Parzefall and others 12 
(2014). Magnetic resonance imaging features of Toxoplasma gondii encephalitis have 13 
not yet been described for dogs, but it is known to cause focal granuloma formation 14 
both in the forebrain (Pfohl and others 2005; Falzone and others 2008) and the spinal 15 
cord (Alves and others 2011) of cats. The 4 dogs with multifocal or diffuse brain lesions 16 
all had an increased TNCC with a mononuclear pleocytosis but without signs of 17 
presence of lymphoblastic cells. No further diagnostic investigations for lymphoma 18 
were performed. Gliomatosis cerebri is a central nervous system neoplasia that is 19 
mainly affecting brachycephalic breeds (Boxer, Boston Terrier, English Bulldog, Bull 20 
Mastiff) and MRI mainly reveals single lesions in thalamus and/or brainstem, although 21 
the cerebrum can be involved and sometimes no lesions are visible (Bentley and others 22 
2014). This differential diagnosis seems less likely in these 4 dogs because of their 23 
breeds and the presence of multifocal or diffuse lesions, but necropsy confirmation is 24 
lacking in those cases. Overall, pitfalls of this study are its retrospective character, the 25 
lack of histopathological confirmation and infectious disease testing in a number of 1 
cases. In contrary, MUA is considered a clinical and imaging diagnosis in cases were 2 
definitive brain histology is lacking.  3 
 4 
Conclusions 5 
Twenty-five per cent of dogs diagnosed with MUA in this study were 6 
considered large breed dogs. Ignoring this population of dogs would underestimate the 7 
prevalence of MUA in the overall canine population. Large breed dogs presented 8 
significantly more often with a decreased mentation compared to small/medium breed 9 
dogs. The MST was not significantly different between small/medium and large breed 10 
dogs, 281 and 106 days respectively, leading to a guarded prognosis for all dogs 11 
diagnosed with MUA and receiving immunosuppressive treatment. In conclusion, 12 
MUA should be considered as a differential diagnosis in dogs other than small or toy 13 
breeds that have signs suggestive of inflammatory brain disease.  14 
 15 
 16 
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Tables  1 
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Table 1 3 
Variable 
Small/mediu
m breed dogs 
(n=83) 
Large breed dogs 
(n=28) 
P value/FDR 
Signalment       
   Age (months)  52 (6 – 146) 60 (10 – 120)  0.7373/0.0678 
   Male  44 (53%) 17 (61%)  0.0653/0.0143 
   Female  39 (47%) 11 (39%)  0.0653/0.0178 
Duration of clinical signs 
prior to diagnosis (days) 
8 (1-180) 5 (1 – 60) 0.0116/0.0071 
Clinical signs       
   Seizures  19 (23%) 10 (36%) 0.2164/0.0286 
   Cluster seizures  13 (16%) 7 (25%)  1.0000/0.0929 
Neuroanatomical 
localisation 
      
   Forebrain  58 (70%) 22 (79%) 0.4875/0.0464 
   Brainstem  53 (64%) 18 (64%) 1.0000/0.0964 
   Central vestibular  27 (33%) 4 (14%) 0.0904/0.0214 
   Abnormal mentation 26 (31%) 25 (89%) <0.0001/0.0036* 
Bloodwork       
   White blood cells 
(.109/l) 
 10.6 (3.52 – 
32.8) 
9.8 (4.66 – 25.1) 0.5888/0.05 
   Neutrophils (.109/l) 
 7.5 (2.4 – 
28.3) 
 7.1 (3.2 – 22.3)  0.4420/0.0429 
   Lymphocytes (.109/l)  1.3 (0.1 – 3.6)  1.2 (0.3 – 2.7)  0.3434/0.0393 
Venous blood gas       
   Lactate (mmol/l)  1.5 (0.6 – 3.6) 1.6 (0.4 – 10.4) 0.8711/0.0786 
CSF analysis       
   TNCC (WBC/mm3)  97 (1 – 2560) 48 (1 – 2220) 0.3360/0.03572 
   Total protein (g/l) 
 0.54 (0.11 – 
3.51) 
 0.43 (0.1 – 8.47)  0.7872/0.0714 
MRI findings       
   Focal lesion  24 (29%) 7 (25%) 0.7163/0.0607 
   Multifocal lesion  57 (69%) 20 (71%) 0.7335/0.0643 
   Diffuse lesion  6 (7%) 2 (7%) 1.0000/0.1 
   Forebrain localisation  66 (80%) 23 (82%) 0.7035/0.0571 
   Brainstem localisation  41 (49%) 20 (71%) 0.0414/0.0107 
   Cerebellar localisation  16 (19%) 5 (18%) 0.8893/0.0821 
   Mass effect  53 (64%) 13 (46%) 0.1297/0.025 
      Brain herniation  34 (41%) 10 (36%) 0.6586/0.0536 
      Caudal transtentorial 
herniation 
 29 (35%) 10 (36%) 0.9097/0.0857 
      Foramen magnum   
herniation 
 23 (28%) 7 (25%) 0.8066/0.075 
      Midline shift  31 (37%) 7 (25%) 0.2534/0.321 
      Flattening gyri/sulci  38 (46%) 13 (46%) 0.9140/0.0893 
 1 
Table 1: Investigated variables in small/medium and large breed dogs diagnosed with 2 
MUA. Values are numbers with their percentage, or a median with interquartile range 3 
between brackets. FDR: false discovery rate. * = P-value below the FDR threshold and 4 
thus considered to be significant.  5 
 6 
Table 2 7 
 1 
Breed Age 
at 
pres
enta
tion 
(mo
nths
) 
Dur
atio
n 
clini
cal 
signs 
prio
r to 
pres
enta
tion 
(#d) 
Ser
olog
y or 
PC
R 
on 
CS
F 
perf
orm
ed 
TNC
C 
(WB
C/m
m3)  
TP 
(g/l) 
MRI findings (lesion 
localisation) 
ST 
(d
ay
s) 
PM 
dia
gno
sis 
Akita 36 2 yes 2220 4,65 Multifocal lesions 
brainstem and spinal 
cord  
2 NP 
Bernese 
Mountai
n Dog 
45 21 yes 12 0,38 Multifocal lesions 
forebrain and 
brainstem 
12
0 
NP 
Border 
Collie 
70 7 yes 300 2,47 Multifocal lesions 
forebrain and 
cerebellum 
92 AL
IV
E 
Boxer 68 60 no NP NP Multifocal lesions 
forebrain, brainstem 
and cerebellum 
1 G
M
E 
Cross 
Breed 
85 5 no 23 0,26 Focal lesion forebrain 15
80 
AL
IV
E 
Cross 
Breed 
64 30 no 1255 1,31 Multifocal lesions 
forebrain, brainstem 
and spinal cord 
5 NP 
Cross 
Breed 
23 3 yes 555 1,92 Focal lesion 
brainstem 
1 G
M
E 
Cross 
Breed 
26 4 yes 1090 8,47 Focal lesion 
brainstem 
10
95 
AL
IV
E 
Cross 
Breed 
12 5 yes 90 0,62 Multifocal lesions 
forebrain, brainstem 
and cerebellum 
27
08 
AL
IV
E 
Curly-
Coated 
Retriever 
63 38 yes 80 0,78 Multifocal lesions 
forebrain, brainstem 
and cerebellum 
21
90 
AL
IV
E 
English 
Springer 
Spaniel 
61 5 yes 62 0,6 Multifocal lesions 
forebrain and 
brainstem 
29
50 
AL
IV
E 
English 
Springer 
Spaniel 
60 2 no 17 0,75 Diffuse lesions 
forebrain 
1 NP 
English 
Springer 
Spaniel 
47 1 yes 12 0,16 Multifocal lesions 
brainstem 
72 AL
IV
E 
English 
Springer 
Spaniel 
61 5 no 29 0,23 Multifocal lesions 
forebrain and 
brainstem 
20
39 
AL
IV
E 
English 
Springer 
Spaniel 
39 1 yes 173 0,68 Focal lesion 
brainstem 
11
87 
AL
IV
E 
English 
Springer 
Spaniel 
78 2 yes NP NP Multifocal lesions 
forebrain, brainstem 
and cerebellum 
70
0 
AL
IV
E 
German 
Wirehair
ed 
Pointer 
10 4 yes 12 0,23 Multifocal lesions 
forebrain and 
brainstem 
97
5 
AL
IV
E 
Golden 
Retriever 
75 7 yes 1 0,21 Multifocal lesions 
forebrain and 
brainstem 
1 G
M
E 
Golden 
Retriever 
60 7 yes 22 0,46 Multifocal lesions 
forebrain and 
brainstem 
18
56 
AL
IV
E 
Great 
Dane 
60 2 yes 40 0,1 Multifocal lesions 
forebrain 
1 NP 
Japanese 
Akita 
20 2 no 51 0,41 Multifocal lesions 
forebrain and 
brainstem 
1 NP 
Labrador 120 13 yes 8 0,1 Focal lesion forebrain 3 N
M
E 
Labrador 47 7 yes 3 0,24 Multifocal lesions 
forebrain and 
brainstem 
1 NL
E 
Labrador 27 7 no NP NP Diffuse lesions 
forebrain 
18
4 
AL
IV
E 
Labrador 94 3 no 30 0,43 Multifocal lesions 
forebrain and 
brainstem 
73
0 
AL
IV
E 
Shar-Pei 36 9 yes NP NP Multifocal lesions 
forebrain 
21
29 
AL
IV
E 
Siberian 
Husky 
30 2 no 68 0,35 Focal lesion forebrain 18 NP 
Welsh 
Springer 
Spaniel 
89 21 yes 675 5,56 Multifocal lesions 
forebrain and 
brainstem 
3 G
M
E 
  1 
Table 2: Overview of breed, age, duration of clinical signs prior to diagnosis, 1 
infectious disease testing results, TNCC in CSF, TP concentration in CSF, MRI 2 
findings, ST and post mortem (PM) necropsy findings for the large breed dogs 3 
included in this study. NP: not performed.  4 
 5 
 6 
  7 
Figure legends 1 
 2 
Figure 1 3 
 4 
Figure 1: Kaplan-Meier survival curve comparing the percentage of survival in 5 
small/medium (full black line) and large (dotted line) breed dogs. Results were 6 
censored for dogs that were still alive at time of data capture (single little blocks).  7 
 8 
